PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35241098-6	2022	RESULTS: CoQ10 treatment significantly increased serum adiponectin levels at week 12 (165 (0, 362) ng/mL, p < 0.001) and at week 24 (523 (0, 1056) ng/mL, p < 0.001)), which was significant different compared with placebo (p < 0.001).	coenzyme Q10	9-14	adiponectin, C1Q and collagen domain containing	Homo sapiens	55-66	
35241098-7	2022	The increase of adiponectin was negative associated with decrease in index of homeostasis model assessment of insulin resistance (HOMA-IR, r = - 0.465, p = 0.001), triglyceride (TG, r = - 0.297, p = 0.047), and low-density lipoprotein cholesterol (LDL-c, r = - 0.440, p = 0.002) at week 24 only in CoQ10-treated group.	coenzyme Q10	298-303	adiponectin, C1Q and collagen domain containing	Homo sapiens	16-27	
35241098-13	2022	The beneficial effect of CoQ10 on glucolipid profile was mediated by adiponectin.	coenzyme Q10	25-30	adiponectin, C1Q and collagen domain containing	Homo sapiens	69-80	
32375340-4	2020	Results from the current meta-analysis, involving 318 participants, showed that CoQ10 supplementation in individuals with metabolic syndrome increased adiponectin levels when compared to those on placebo (SMD: 1.44 [95% CI: -0.13, 3.00]; I2 = 96%, p < 0.00001).	coenzyme Q10	80-85	adiponectin, C1Q and collagen domain containing	Homo sapiens	151-162